Ngā hua rapu - Janet L. Karlix

  • E whakaatu ana i te 1 - 5 hua o te 5
Whakamahine hua
  1. 1
    Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

    Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study mā Barry D. Kahan, Janet L. Karlix, Ronald M. Ferguson, Alan B. Leichtman, Shamkant Mulgaonkar, Thomas A. Gonwa, Andrej Skerjanec, Robert Schmouder, Lawrence Chodoff

    I whakaputaina 2003
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    OBESITY DOES NOT PORTEND A BAD OUTCOME FOR KIDNEY TRANSPLANT RECIPIENTS

    OBESITY DOES NOT PORTEND A BAD OUTCOME FOR KIDNEY TRANSPLANT RECIPIENTS mā Richard J. Howard, Van B. Thai, Pamela R. Patton, Alan W. Hemming, Alan Reed, Willem J. Van der Werf, Shiro Fujita, Janet L. Karlix, Juan C. Scornik

    I whakaputaina 2002
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer

    A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer mā Gerald S. Falchook, James A. Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet L. Karlix, Gayle P. Pouliot, Maureen M. Hattersley, Eric T. Gangl, Gareth D. James, Jeff Thompson, Deanna L. Russell, Bhavickumar Patel, Rakesh Kumar, Emerson A. Lim

    I whakaputaina 2024
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

    First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma mā Erika Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer, Janet L. Karlix, Jorge Zerón-Medina, Giulia Fabbri, Paola Marco‐Casanova, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick D. Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

    Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors mā Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: